Canada Human Fibrinogen Concentrates Market Size, Share & Industry Analysis, By Product (Fibryga, RiaSTAP, and Others), By Application (Congenital Fibrinogen Deficiency, Acquired Fibrinogen Deficiency & Surgical Procedures, and Others), By End User (Hospitals & ASCs, Specialty Clinics, and Others), and Forecasts, 2025-2032

The Canada human fibrinogen concentrates market size was valued at USD 7.6 million in 2024. The market is projected to grow from USD 8.0 million in 2025 to USD 13.8 million by 2032, exhibiting a CAGR of 8.12% during the forecast period. 

Human fibrinogen concentrates are essential plasma-derived therapies used in the management of congenital fibrinogen deficiencies, acquired bleeding disorders, trauma, and surgical bleeding. The Canada human fibrinogen concentrates market is experiencing steady growth due to increased recognition of congenital fibrinogen deficiency, rising demand for advanced hemostatic therapies, and expanded use in trauma and perioperative care. Additionally, the growing adoption of purified and virus-inactivated fibrinogen concentrates over traditional cryoprecipitate is also propelling market growth.

The industry is dominated by Octapharma AG and CSL Behring, and these companies focus on strategic initiatives to maintain their market positions in the Canada human fibrinogen concentrates market.

MARKET DYNAMICS

MARKET DRIVERS:

Increasing Incidence of Bleeding Disorders to Propel Market Growth 

The increasing incidence of bleeding disorders is prominently driving the Canada human fibrinogen concentrates market growth. With the increasing awareness and diagnosis rate of bleeding disorders, more patients with hemophilia, von Willebrand disease, and rare inherited bleeding disorders, including fibrinogen deficiency, are being identified and receiving medical attention. This expanding patient pool translates into more treated bleeding episodes, surgeries, and prophylaxis courses where fibrinogen replacement is required, particularly for congenital fibrinogen deficiency and complex acquired coagulopathies.

• For instance, according to the data provided by the Canadian Hemophilia Society in June 2024, hemophilia A affects around 3,900 Canadians.

MARKET RESTRAINTS:

High Cost of Product to Restrict Market Growth 

Fibrinogen concentrates remain significantly more expensive than cryoprecipitate, creating budgetary pressure for hospitals, restraining the Canadian market growth. The high costs of fibrinogen concentrate products limit the usage of these products across all surgical and trauma cases. As a result, many institutions continue to rely on cheaper cryoprecipitate for fibrinogen replacement despite the safety, dosing, and logistical benefits of HFC. This pricing pressure hampers market growth to a certain extent.

• For instance, according to a study published in the National Center for Biotechnology Information (NCBI) in January 2023, Fibrinogen concentrates were more expensive than cryoprecipitate in Canada.

MARKET OPPORTUNITIES:

Shifting Inclination of Hospitals toward Patient Blood Management (PBM) Offers Significant Growth Opportunities

Hospitals are moving toward PBM models that favor targeted factor concentrates over large-volume blood products. Research studies of fibrinogen concentrates in cardiac surgery show that standardized dosing plus viscoelastic testing (ROTEM/TEG) can correct hypofibrinogenemia quickly and help optimize transfusion use. With the increasing number of Canadian centers adopting these algorithms, fibrinogen concentrates can scale with each new massive hemorrhage protocol or cardiac surgery pathway that embeds fibrinogen concentrate as first-line replacement.

CANADA HUMAN FIBRINOGEN CONCENTRATES MARKET TRENDS:

Increased Clinical Adoption for Cardiac and Trauma Surgery Is a Significant Trend Observed in Canada Human Fibrinogen Concentrates Market

Increased clinical adoption of human fibrinogen concentrate (HFC) in cardiac and trauma surgery is a prominent trend observed in the Canadian market. Hospitals across Canada are increasingly integrating fibrinogen concentrates into massive transfusion protocols and perioperative bleeding management, in turn driving market growth. Additionally, supportive clinical guidelines, along with real-world data evidence are accelerating the penetration of HFC into cardiac ORs and trauma surgeries.

MARKET CHALLENGES:

Dependence on Global Manufacturers to Pose a Significant Challenge for the Market 

Canada heavily relies on international manufacturers for finished fibrinogen products, making supply vulnerable to global plasma shortages, thereby posing a significant challenge to overall market growth. This dependence means that any disruption in international plasma collection or bottlenecks in fractionation capacity can constrain the availability of fibrinogen concentrates and other plasma products. 

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Wide Availability of Product Propelled Segmental Growth

Based on product, the market is divided into Fibryga, RiaSTAP, and others. 

To know how our report can help streamline your business, Speak to Analyst

The RiaSTAP segment dominated the Canadian market with the largest market share. The product has high penetration and strong uptake among younger hematologists and tertiary centers across Canada.

• For instance, many centers continue to rely on RiaSTAP as their default congenital product.

The Fibryga segment is expected to grow at a CAGR of 14.13% during the forecast period.

By Application

Congenital Fibrinogen Deficiency Segment Dominated due to Its High Prevalence

Based on application, the market is divided into congenital fibrinogen deficiency, acquired fibrinogen deficiency & surgical procedures, and others.

In 2024, the congenital fibrinogen deficiency segment captured the largest Canada human fibrinogen concentrates market share.  The segment is set to hold a 54.4% share in 2025. The rising prevalence of this disorder is majorly driving segment growth.

• For instance, Both the FC products currently available in Canada are mainly focused on congenital fibrinogen deficiency.

The acquired fibrinogen deficiency & surgical procedures segment is projected to grow at a CAGR of 13.03% during the study period. 

By End User

High Usage of HFC Boosted the Hospitals & ASCs Segment

Based on end user, the market is segmented into specialty clinics, hospitals & ASCs, and others.

In 2024, the hospitals & ASCs segment captured the largest Canada human fibrinogen concentrates market share. The hospitals are increasingly using human fibrinogen concentrate (HFC), especially to manage bleeding and surgical prophylaxis. The rising number of awareness programs and collaboration between the health centers further propel the segment’s growth. Furthermore, the hospitals & ASCs segment is set to hold an 82.4% share in 2025.

The specialty clinics segment is projected to grow at a CAGR of 7.45% during the study period. 

COMPETITIVE LANDSCAPE

Key Industry Players:

Strategic Collaborations with Regulatory Bodies to Strengthen Their Market Position

The Canada human fibrinogen concentrates market shows a highly consolidated structure, with key players such as CSL Behring LLC., and Octapharma AG accounting for the maximum share of the market in 2024. Agreements with Héma-Québec and Canadian Blood Services (CBS) have resulted in the leading position of these companies in the market.

Other notable players in the market are Grifols S.A. and LFB. These companies are focusing on launching their products in the Canadian market.

LIST OF KEY HUMAN FIBRINOGEN CONCENTRATES MARKET PROFILED:

• CSL Behring LLC. (U.S.)
• Octapharma AG (Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• August 2020: Octapharma Canada announced that Health Canada approved Fibryga (Human Fibrinogen Concentrate, HFC) for use in the treatment of acquired fibrinogen deficiency (AFD).

REPORT COVERAGE

The Canada human fibrinogen concentrates market analysis provides a detailed study of the market size & forecast by all the market segments included in the report. The report also provides insights into market dynamics and trends expected to drive the market during the forecast period. The market report also comprises key aspects, such as an overview of technological 

advancements, product launches, insights on strategic partnerships, mergers & acquisitions, and key industry developments in Canada. The market forecast also provides a detailed competitive landscape, including market share and profiles of major industry players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation